Importance of circulating antibodies in protection against meningococcal disease
Open Access
- 1 August 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Human Vaccines & Immunotherapeutics
- Vol. 8 (8), 1029-1035
- https://doi.org/10.4161/hv.20473
Abstract
Neisseria meningitidis infection results in life-threatening illnesses, including bacteremia, sepsis and meningitis. Early diagnosis and treatment are a challenge due to rapid disease progression, resulting in high mortality and morbidity in survivors. Disease can occur in healthy individuals, however, risk of infection is higher in patients with certain risk factors. N meningitidis carriage and case-fatality rates are high in adolescents and young adults. The absolute incidence of meningococcal disease has decreased partially due to increasing meningococcal vaccination rates. Maintaining protective levels of circulating antibodies by vaccination is necessary for clinical protection against disease. The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices guidelines recommend vaccination for all individuals aged 11 through 12 years, followed by a booster dose at age 16 years for maintenance of protective antibody levels throughout the high-risk years. Despite these guide...This publication has 65 references indexed in Scilit:
- Meningococcal Conjugate Vaccines Policy Update: Booster Dose RecommendationsPEDIATRICS, 2011
- Infections of People with Complement Deficiencies and Patients Who Have Undergone SplenectomyClinical Microbiology Reviews, 2010
- Functional T-Cell Deficiency in Adolescents Who Experience Serogroup C Meningococcal Disease despite Receiving the Meningococcal Serogroup C Conjugate VaccineClinical and Vaccine Immunology, 2010
- Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd ImmunityClinical and Vaccine Immunology, 2010
- Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humansBlood, 2009
- Booster Vaccinations: Can Immunologic Memory Outpace Disease Pathogenesis?PEDIATRICS, 2009
- Global epidemiology of meningococcal diseaseVaccine, 2009
- Evidence of a Functional B-Cell Immunodeficiency in Adults Who Experience Serogroup C Meningococcal DiseaseClinical and Vaccine Immunology, 2009
- Meningococcal Disease in South Africa, 1999–2002Emerging Infectious Diseases, 2007
- Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in EnglandClinical and Vaccine Immunology, 2003